International researchers have officially identified a distinct neurological condition, Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), which may explain why dementia diagnoses are ofen missed or misattributed in the very elderly. Affecting an estimated 10-33% of those over 65, LATE presents with similar symptoms to Alzheimer’s disease – especially memory loss – but stems from a different underlying biological process. This newly recognized syndrome highlights the complexities of dementia diagnosis and could reshape how clinicians approach cognitive decline in older adults, as well as possibly reinterpret data from past Alzheimer’s drug trials.
Newly Identified Condition May Explain Misdiagnoses of Dementia in the Very Elderly
International researchers have officially recognized a new neurological syndrome linked to memory loss in older adults, a condition that has been frequently mistaken for Alzheimer’s disease for years. The condition has been named Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE.
Studies indicate that LATE affects approximately 10% of individuals over the age of 65 and may be present in as many as one-third of those over 85. In many cases, patients have been diagnosed and treated for Alzheimer’s disease despite exhibiting a different type of brain change. Accurate diagnosis is crucial for appropriate care and potential treatment strategies.
The recognition of LATE came after analyses conducted by researchers at specialized centers for aging and dementia. By reviewing brain scans and autopsy data, scientists observed that a significant proportion of dementia cases didn’t align with the classic patterns of Alzheimer’s disease.
A Different Dementia, But With Similar Symptoms
LATE primarily causes memory lapses and difficulty recalling names or identifying objects – symptoms also common in Alzheimer’s. This similarity explains why diagnostic confusion has been so prevalent over the years.
However, unlike Alzheimer’s, LATE doesn’t initially impact functions like planning, organization, and task execution to the same degree. This often leads to the disease being considered slower progressing when it occurs in isolation.
What Happens in the Brain
The key difference between the two diseases lies in the underlying biological mechanisms. While Alzheimer’s is linked to the buildup of beta-amyloid plaques and Tau protein, LATE involves abnormal deposits of the TDP-43 protein.
Normally, this protein functions within the cell nucleus, helping to regulate DNA and RNA activity. In LATE, it shifts to other areas of the cell, forming clumps that damage essential brain regions.
One of the most affected areas is the hippocampus, which is responsible for forming memories. Research shows this region may experience greater volume reduction in people with LATE compared to those with Alzheimer’s alone.
Genetic Factor Increases Risk
Although the exact cause of LATE remains unknown, scientists have identified a higher incidence of the syndrome in individuals with the Apolipoprotein E4 genetic variant – the same variant associated with an increased risk of Alzheimer’s and vascular problems.
This genetic overlap helps explain why the two diseases can coexist in the same patient, a situation that can make symptoms more aggressive and progression faster.
Treatment Remains Limited
Currently, there is no specifically approved treatment for LATE. Medications used for Alzheimer’s tend to be ineffective in patients who have only LATE, as they target substances absent in this type of dementia.
Experts also believe LATE may have negatively influenced past clinical trials of Alzheimer’s drugs, as some participants likely had the syndrome unknowingly.
First Tests with a Drug Have Begun
With the official recognition of the disease, the first clinical trial specifically for LATE is underway in the United States. The study is evaluating the use of nicorandil, a medication used in some countries for heart problems.
The research is following older adults with mild memory complaints for two years, seeking to determine if the drug can slow disease progression.
For scientists, recognizing LATE represents an important advancement in dementia diagnosis and may change how doctors evaluate cognitive decline in very elderly individuals.
Follow Portal 6 on Google News to stay up to date on everything!
